Anti-tumor effect of Fasudil, a ROCK inhibitor, on gastric cancer in mice

Chengcheng Yang; Yan Miao; Qiang Yu; Xiangjie Wang

doi:10.53730/ijhs.v7n3.14624

Authors

Chengcheng Yang The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China
Yan Miao The First Affiliated Hospital of Air Force Medical University, Xi 'an, China
Qiang Yu The First Affiliated Hospital of Air Force Medical University, Xi 'an, China
Xiangjie Wang
waxj0732@163.com
The First Affiliated Hospital of Air Force Medical University, Xi 'an, China

Keywords:

apoptosis, Fasudil, gastric cancer, inflammation mediators, oxidative stress

Abstract

Gastric cancer remains one of the most common malignant tumors and a leading cause of death. However, there are few reports about the anti-tumor effect of Fasudil (Fas) on the stomach. Establishment of nude mice model of gastric cancer to evaluate the anti-tumor effect of Fas. The mice in each group were weighed every week. Serum and tumor tissue cytokines are detected by commercial kits. Serum and tumor tissue superoxide dismutase and malondialdehyde were detected by commercial kits. Histopathological changes in the tumor were detected by HE staining. Expression of ROS/ TXNIP/NLRP3/Caspase-1 pathway in tumor tissues was detected by Western blot. Our results showed that Fas increased and decreased the body weight of tumor mice, increased serum and tumor tissue cytokines contents of tumor mice, increased serum and tumor tissue oxidative stress of tumor mice, and increased Bax, Caspase-3, Caspase-9 protein expression, reduced Bcl-2 protein expression, also regulated ROS/TXNIP/NLRP3/Caspase-1 pathway expression. Our experiments show that Fas has a significant anti-gastric cancer effect, and its mechanism is related to the regulation of oxidative stress, inflammation and apoptosis in vivo.

Downloads

Download data is not yet available.

References

Broz, P., & Dixit, V. M. (2016). Inflammasomes: mechanism of assembly, regulation and signalling. Nature Reviews Immunology, 16(7), 407-420.

Deng, L., Li, G., Li, R., Liu, Q., He, Q., & Zhang, J. (2010). Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer biology & therapy, 9(11), 875-884.

Doonan, F., & Cotter, T. G. (2008). Morphological assessment of apoptosis. Methods, 44(3), 200-204. https://doi.org/10.1016/j.ymeth.2007.11.006

Freeman, S., Brough, D., & El-Sharkawy, L. (2020). Inhibiting the NLRP3 Inflammasome. Molecules, 25(5533).

Guerra, F. S., Oliveira, R. G. D., Fraga, C. A. M., Mermelstein, C. D. S., & Fernandes, P. D. (2017). ROCK inhibition with Fasudil induces beta-catenin nuclear translocation and inhibits cell migration of MDA-MB 231 human breast cancer cells. Scientific reports, 7(1), 13723.

Jiang, D., Chen, S., Sun, R., Zhang, X., & Wang, D. (2018). The NLRP3 inflammasome: role in metabolic disorders and regulation by metabolic pathways. Cancer letters, 419, 8-19. https://doi.org/10.1016/j.canlet.2018.01.034

Lv, Z., Ding, Y., Cao, W., Wang, S., & Gao, K. (2022). Role of RHO family interacting cell polarization regulators (RIPORs) in health and disease: Recent advances and prospects. International Journal of Biological Sciences, 18(2), 800.

Macias-Alvia, A. M., Zambrano-Santos, R. O., Zambrano-Ubillus, R. P., & Ubillús-Saltos, S. (2022). Self-care in primary health care in the nursing career. International Journal of Health Sciences, 6(3), 1671–1684. https://doi.org/10.53730/ijhs.v6n3.13694

Pachathundikandi, S. K., & Backert, S. (2018). Helicobacter pylori controls NLRP3 expression by regulating hsa-miR-223-3p and IL-10 in cultured and primary human immune cells. Innate immunity, 24(1), 11-23.

Ravizza, T., Balosso, S., & Vezzani, A. (2011). Inflammation and prevention of epileptogenesis. Neuroscience letters, 497(3), 223-230. https://doi.org/10.1016/j.neulet.2011.02.040

Russo, A., Terrasi, M., Agnese, V., Santini, D., & Bazan, V. (2006). Apoptosis: a relevant tool for anticancer therapy. Annals of Oncology, 17, vii115-vii123. https://doi.org/10.1093/annonc/mdl963

Saif, M. W., Makrilia, N., Zalonis, A., Merikas, M., & Syrigos, K. (2010). Gastric cancer in the elderly: an overview. European Journal of Surgical Oncology (EJSO), 36(8), 709-717. https://doi.org/10.1016/j.ejso.2010.05.023

Sarkar, D., & Fisher, P. B. (2006). Molecular mechanisms of aging-associated inflammation. Cancer letters, 236(1), 13-23. https://doi.org/10.1016/j.canlet.2005.04.009

Sies, H. (2018). On the history of oxidative stress: Concept and some aspects of current development. Current Opinion in Toxicology, 7, 122-126. https://doi.org/10.1016/j.cotox.2018.01.002

Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020). Gastric cancer. The Lancet, 396(10251), 635-648.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.

Tanaka, K., Minami, H., Kota, M., Kuwamura, K., & Kohmura, E. (2005). Treatment of cerebral vasospasm with intra-arterial fasudil hydrochloride. Neurosurgery, 56(2), 214-223.

Thrift, A. P., & El-Serag, H. B. (2020). Burden of gastric cancer. Clinical Gastroenterology and Hepatology, 18(3), 534-542. https://doi.org/10.1016/j.cgh.2019.07.045

Wang, H., Luo, Q., Feng, X., Zhang, R., Li, J., & Chen, F. (2018). NLRP3 promotes tumor growth and metastasis in human oral squamous cell carcinoma. BMC cancer, 18, 1-10.

Wang, N., Guan, P., Zhang, J. P., Chang, Y. Z., Gu, L. J., Hao, F. K., ... & Chu, L. (2011). Preventive effects of fasudil on adriamycin-induced cardiomyopathy: possible involvement of inhibition of RhoA/ROCK pathway. Food and chemical toxicology, 49(11), 2975-2982. https://doi.org/10.1016/j.fct.2011.06.080

Wang, Q., Song, L. J., Ding, Z. B., Chai, Z., Yu, J. Z., Xiao, B. G., & Ma, C. G. (2022). Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases. Neural regeneration research, 17(12), 2623.

Yamashita, K., Kotani, Y., Nakajima, Y., Shimazawa, M., Yoshimura, S. I., Nakashima, S., ... & Hara, H. (2007). Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. Brain research, 1154, 215-224. https://doi.org/10.1016/j.brainres.2007.04.013

Zhang, X., & Wu, N. (2018). Fasudil inhibits proliferation and migration of Hep-2 laryngeal carcinoma cells. Drug design, development and therapy, 373-381.